In yesterday’s Wall Street session, GSK plc (NYSE:GSK) shares traded at $34.69, down -2.06% from the previous session.
As of this writing, 21 analysts cover GSK plc (NYSE:GSK). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $65.62 and a low of $32.94, we find $40.00. Given the previous closing price of $35.42, this indicates a potential upside of 12.93 percent. GSK stock price is now -3.91% away from the 50-day moving average and 1.13% away from the 200-day moving average. The market capitalization of the company currently stands at $70.48B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
There are 10 analysts who have given it a hold rating, whereas 8 have given it a buy rating. Brokers who have rated the stock have averaged $41.71 as their price target over the next twelve months.
.
A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GSK stock. A new stake in GSK plc shares was purchased by HOLOCENE ADVISORS, LP during the first quarter worth $41,025,000. OPTIVER HOLDING B.V. invested $27,558,000 in shares of GSK during the first quarter. In the first quarter, JEFFERIES GROUP LLC acquired a new stake in GSK plc valued at approximately $10,361,000. OWL CREEK ASSET MANAGEMENT, L.P. acquired a new stake in GSK for approximately $9,906,000. CANTOR FITZGERALD, L. P. purchased a new stake in GSK valued at around $9,158,000 in the second quarter. In total, there are 910 active investors with 13.80% ownership of the company’s stock.
Wednesday morning saw GSK plc (NYSE: GSK) opened at $35.04. During the past 12 months, GSK plc has had a low of $28.47 and a high of $45.91. As of last week, the company has a debt-to-equity ratio of 1.77, a current ratio of 1.00, and a quick ratio of 0.70. According to the stock market information, the enterprise value for the company is $89.97B, which is based on a 12.68 price-to-earnings ratio, a 2.54 price-to-earnings-growth ratio, and a beta of 0.69. The fifty day moving average price for GSK is $36.12 and a two-hundred day moving average price translates $34.27 for the stock.
The latest earnings results from GSK plc (NYSE: GSK) was released for Mar, 2023. The net profit margin was 50.30% and return on equity was 122.20% for GSK. The company reported revenue of $8.44 billion for the quarter, compared to $13.12 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -35.65 percent. For the current quarter, analysts expect GSK to generate $8.5B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 07/13/2023. Investors who held shares on 05/19/2023 were paid a $0.347508 dividend. On an annualized basis, this represents a $1.39 dividend and a 4.02% percent yield. There was an ex-dividend date of 05/18/2023 for this dividend.
GSK plc(GSK) Company Profile
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.
